Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

Summary Background Our understanding of the genetic basis of predisposition to psoriasis is increasing exponentially due to the progress of genetic studies. However, so far little is known about genetic predisposition in relation to the response to psoriasis treatments. Recent data identified geneti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2013-08, Vol.169 (2), p.458-463
Hauptverfasser:	Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., Chimenti, S., Costanzo, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Biological and medical sciences Biological Products - therapeutic use Cornified Envelope Proline-Rich Proteins - genetics Dermatology DNA-Binding Proteins - genetics Female Gene Deletion HLA-C Antigens - genetics Humans Interleukin-12 - antagonists & inhibitors Interleukin-23 - antagonists & inhibitors Male Medical sciences Middle Aged Polymorphism, Genetic - genetics Psoriasis - genetics Psoriasis. Parapsoriasis. Lichen Ustekinumab Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!